Personalizing stem cell research and therapy: The arduous road ahead or missed opportunity?

Current Pharmacogenomics and Personalized Medicine

Volumn 8, Issue 1, 2010, Pages 25-36

  Patel, S A ^a,b   King, C C ^b   Lim, P K ^b   Habiba, U ^b   Dave, M ^b   Porecha, R ^b   Rameshwar, P ^b  

^a University of Medicine and Dentistry of New Jersey   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Graft versus host disease; Immunosuppression; Mesenchymal stem cells; Microenvironment; Personalized therapeutics

Indexed keywords

BORTEZOMIB; CORTICOSTEROID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; THYMOCYTE ANTIBODY; VORINOSTAT;

ACUTE LEUKEMIA; ADULT STEM CELL; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARCINOGENICITY; CATARACT; CELL DIFFERENTIATION; CELL FATE; CELL HETEROGENEITY; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG MECHANISM; EMBRYONIC STEM CELL; GLAUCOMA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL; HEMOGLOBINOPATHY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION; MEDICAL RESEARCH; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROENVIRONMENT; NEURAL STEM CELL; OSTEOLYSIS; REVIEW; SIDE EFFECT; TREATMENT PLANNING; WEIGHT GAIN;

EID: 77950254595     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/1875692111008010025     Document Type: Review

References (106)

1. Bates S. Progress towards personalized medicine. Drug Discov Today 2009; [In press].
2. Ely S. Personalized medicine: individualized care of cancer patients. Transl Res 2009; 154(6): 303-308
3. Nelson TJ, Behfar A, Yamada S, et al. Stem cell platforms for regenerative medicine. Clin Transl Sci 2009; 2(3): 222-227
4. Kim PG, Daley GQ. Application of induced pluripotent stem cells to hematologic disease. Cytotherapy 2009; 11(8): 980-989
5. Baker M. Stem-cell drug fails crucial trial. (2009). [Accessed November 28, 2009] Available from: http://www.nature.com/news/2009/090909/full/news.2009. 894.html
6. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371(9624): 1579-1586
7. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363(9419): 1439-1441
8. McNearney TA, Hunnicutt SE, Fischbach M, et al. Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine. J Rheumatol 2009; [In press]
9. Koppula PR, Chelluri LK, Polisetti N, et al. Histocompatibility testing of cultivated human bone marrow stromal cells - a promising step towards pre-clinical screening for allogeneic stem cell therapy. Cell Immunol 2009; 259(1): 61-65
10. Tang KC, Trzaska KA, Smirnov SV, et al. Down-regulation of MHC II in mesenchymal stem cells at high IFN-gamma can be partly explained by cytoplasmic retention of CIITA. J Immunol 2008; 180(3): 1826-1833
11. Lu X, Liu T, Gu L, et al. Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets. Transpl Immunol 2009 [E-pub Aug 18].
12. Erlach KC, Böhm V, Knabe M, et al. Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection. Med Microbiol Immunol 2008; 197(2): 167-178
13. Xu L, Ryugo DK, Pongstaporn T, et al. Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J Comp Neurol 2009; 514(4): 297-309.
14. Barry F, Boynton R, Murphy M, et al. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem Biophys Res Commun 2001; 289(2): 519-524
15. Greco SJ, Rameshwar P. Enhancing effect of IL-1alpha on neurogenesis from adult human mesenchymal stem cells: implication for inflammatory mediators in regenerative medicine. J Immunol 2007; 179(5): 3342-3350
16. Greco SJ, Zhou C, Ye JH, et al. An interdisciplinary approach and characterization of neuronal cells transdifferentiated from human mesenchymal stem cells. Stem Cells Dev 2007; 16(5): 811-826
17. Nasef A, Mazurier C, Bouchet S, et al. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol 2008; 253(1-2): 16-22.
18. Rameshwar P. Casting doubt on the safety of "off-the-shelf" mesenchymal stem cells for cell therapy. Mol Ther 2009; 17(2): 216-218
19. Ge W, Jiang J, Baroja ML, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009; 9(8): 1760-1772
20. Potian JA, Aviv H, Ponzio NM, et al. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171(7): 3426-3434
21. Traggiai E, Volpi S, Schena F, et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008; 26(2): 562-569
22. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449(7162): 557-563
23. Casiraghi F, Azzollini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181(6): 3933-3946
24. Gonzalez MA, Gonzalez-Rey E, Rico L, et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009; 136(3): 978-989
25. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106(5): 1755-1761
26. Krampera M, Pasini A, Pizzolo G, et al. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol 2006; 6(4): 435-441
27. Kode JA, Mukherjee S, Joglekar MV, et al. Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 2009; 11(4): 377-391
28. Buchholz S, Ganser A. Hematopoietic stem cell transplantation. Indications, foundations and perspective. Internist 2009; 50(5): 572-580
29. Wang M, Tan J, Coffey A, et al. Signal transducer and activator of transcription 3-stimulated hypoxia inducible factor-1alpha mediates estrogen receptor-alpha-induced mesenchymal stem cell vascular endothelial growth factor production. J Thorac Cardiovasc Surg 2009; 138(1): 163-171
30. Vinardell T, Thorpe SD, Buckley CT, et al. Chondrogenesis and Integration of Mesenchymal Stem Cells Within an In Vitro Cartilage Defect Repair Model. Ann Biomed Eng 2009; 37(12): 2556-2564
31. Zhou G, Zhang X, Wu J, et al. 5-azacytidine facilitates osteogenic gene expression and differentiation of mesenchymal stem cells by alteration in DNA methylation. Cytotechnology 2009; [E-pub ahead of print].
32. Zhang Y, Chu Y, Shen W, et al. Effect of 5-azacytidine induction duration on differentiation of human first-trimester fetal mesenchymal stem cells towards cardiomyocyte-like cells. Interact Cardiovasc Thorac Surg 2009; 9(6): 943-946
33. Siepe M, Thomsen AR, Duerkopp N, et al. Human neonatal thymus-derived mesenchymal stromal cells: characterization, differentiation, and immunomodulatory properties. Tissue Eng Part A 2009; 15(7): 1787-1796
34. Huang CH, Chen MH, Young TH, et al. Interactive effects of mechanical stretching and extracellular matrix proteins on initiating osteogenic differentiation of human mesenchymal stem cells. J Cell Biochem 2009; 108(6): 1263-1273
35. Trzaska KA, Reddy BY, Munoz JL, et al. Loss of RE-1 silencing factor in mesenchymal stem cell-derived dopamine progenitors induces functional maturity. Mol Cell Neurosci 2008; 39(2): 285-290
36. Trzaska KA, Kuzhikandathil EV, Rameshwar P. Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. Stem Cells 2007; 25(11): 2797-2808
37. Chevallier N, Anagnostou F, Zilber S, et al. Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials 2010; 31(2): 270-278
38. Solorio LD, Fu AS, Hernández-Irizarry R, et al. Chondrogenic differentiation of human mesenchymal stem cell aggregates via controlled release of TGF-beta1 from incorporated polymer microspheres. J Biomed Mater Res A 2010; 92(3): 1139-1144
39. Park JS, Yang HJ, Woo DG, et al. Chondrogenic differentiation of mesenchymal stem cells embedded in a scaffold by long-term release of TGF-beta3 complexed with chondroitin sulfate. J Biomed Mater Res A 2009 [E-pub March 11].
40. Gou S, Wang C, Liu T, et al. Spontaneous differentiation of murine bone marrow-derived mesenchymal stem cells into adipocytes without malignant transformation after long-term culture. Cells Tissues Organs 2010; 191(3): 185-192
41. Huang Y, Dai ZQ, Ling SK, et al. Gravity, a regulation factor in the differentiation of rat bone marrow mesenchymal stem cells. J Biomed Sci 2009; 16: 87.
42. Freedman AS, Takvorian T, Neuberg D, et al. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 1993; 11(5): 931-936
43. Giglio G, Romito S, Carrozza F, et al. Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2. Int J Hematol 2009; 90(1): 81-86
44. Borrello IM, Levitsky H, Stock W, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009; 114(9): 1736-1745
45. Nishida T, Hudacek M, Kostic A, et al. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res 2009; 15(14): 4759-4768
46. Sun K, Li M, Savers TJ, et al. Differential effects of donor t-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood 2008; 112(4): 1522-1529
47. Hallermalm K, De Greer A, Kiessling R, et al. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res 2004; 64(18): 6775-6782
48. Yi S, Feng X, Wang YP, et al. CD4+ T cells play a major role in xenogeneic human anti-pig cytotoxicity via the Fas/Fas ligand lytic pathway. Transplantation 1999; 67(3): 435.
49. Blazar BR, Murphy WJ. Bone marrow transplantation and approaches to avoid graft-versus-host disease (gvhd). Philos Trans R Soc Lond B Biol Sci 2005; 360(1461): 1747-1767
50. Giralt S, Thall, PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97(3): 631-637
51. McSweeney P, Wagner J, Maloney D, et al. Outpatient PBSC allografts using immunosuppression with low-dose TBI before and cyclosporine (csp) and mycophenolate mofetil (MMF) after transplant. Blood 1998; 92: 519.
52. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008; 20(2): 131-137
53. Lorenz E, Congdon C, Uphoff D. Modification of acute irradiation injury in mice and guinea-pigs by bone marrow injections. Radiology 1952; 58(6): 863-877
54. Welniak LA, Blazar B, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25: 139-170
55. Farag S, Ruppert A, Mrozek K, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol 2005; 23(3): 482-493
56. Truitt RL, Johnson BD. Principles of graft-vs-leukemia reactivity. Biol Blood Marrow Transplant 1995; 1(2): 61-68
57. Greco SJ, Rameshwar P. Microenvironmental considerations in the application of human mesenchymal stem cells in regenerative therapies. Biologics 2008; 2(4): 699-705.
58. Morecki S, Yacovlev E, Gelfand Y, et al. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators. Biol Blood Marrow Transplant 2009; 15(4): 406-415
59. Vodanovia-Jankovic S, Hari P, Jacobs P, et al. NF-kB as a target for the prevention of graft-versus-host disease: compartive efficacy of bortezomib and ps-1145. Blood 2006; 107(2): 827-834
60. Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004; 101(11): 3921-3926
61. Fowler DH. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol 2006; 57(3): 225-244
62. Gregory CA, Ylostalo J, Prockop DJ. Adult bone marrow stem/progenitor (MSCs) are preconditioned by microenvironmental "niches" in culture: a two-stage hypothesis for regulation of MSC fate. Sci STKE 2005; 2005(294): pe37.
63. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: The state of transdifferentiation and modes of tissue repair - current views. Stem Cells 2007; 25(11): 2896-2902
64. Harris DT, Schumaker MJ, Locascio J, et al. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proc Natl Acad Sci USA 1992; 89(21): 10006-10010
65. Cho KJ, Trzaska KA, Greco SJ, et al. Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 alpha. Stem Cells 2005; 23(3): 383-391
66. Ong SY, Dai H, Leong KW. Inducing hepatic differentiation of human mesenchymal stem cells in pellet culture. Biomaterials 2006; 27(22): 4087-4097
67. Jeon SJ, Oshima K, Heller S, et al. Bone marrow mesenchymal stem cells are progenitors in vitro for inner ear hair cells. Mol Cell Neurosci 2007; 34(1): 59-68.
68. Bianco P, Riminucci M, Gronthos S, et al. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 2001; 19(3): 180-192
69. Rameshwar P. Substance P: a regulatory neuropeptide for hematopoiesis and immune functions. Clin Immunol Immunopathol 1997; 85(2): 129-133
70. Rameshwar P, Poddar A, Zhu G, et al. Receptor induction regulates the synergistic effects of substance P with IL-1 and platelet-derived growth factor on the proliferation of bone marrow fibroblasts. J Immunol 1997; 158(7): 3417-3424
71. Sheng H, Wang Y, Jin Y, et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 2008; 18(8): 846-857
72. Wehling N, Palmer GD, Pilapil C, et al. Interleukin-1beta and tumor necrosis factor alpha inhibit chondrogenesis by human mesenchymal stem cells through NF-kappaB-dependent pathways. Arthritis Rheum 2009; 60(3): 801-812
73. Lee WK, Yu SM, Cheong SW, et al. Ectopic expression of cyclooxygenase-2-induced dedifferentiation in articular chondrocytes. Exp Mol Med 2008; 40(6): 721-727
74. Wisel S, Khan M, Kuppusamy ML, et al. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther 2009; 329(2): 543-550
75. Huang AH, Snyder BR, Cheng PH, et al. Putative dental pulp-derived stem/stromal cells promote proliferation and differentiation of endogenous neural cells in the hippocampus of mice. Stem Cells 2008; 26(10): 2654-2663
76. Vindigni V, Michelotto L, Lancerotto L, et al. Isolation method for a stem cell population with neural potential from skin and adipose tissue. Neurol Res 2009; [E-pub ahead of print].
77. Flax J, Aurora S, Yang C, et al. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat Biotechnol 1998; 16(11): 1033-1039
78. Ito S, Natsume A, Shimato S, et al. Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma. Cancer Gene Ther 2009; [E-pub ahead of print].
79. Lacorazza DH, Flax JD, Snyder EY, et al. Expression of human b-hexosaminidase a-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nat Med 1996; 2(4): 424-429
80. Cachon-Gonzalez MB, Wang SZ, Lynch A, et al. Effective gene therapy in an authentic model of tay-sachs-related diseases. Proc Natl Acad Sci USA 2006; 103(27): 10373-10378
81. Sabata Martino S, di Girolamo I, Cavazzin C, et al. Neural precursor cell cultures from gm2 gangliosidosis animal models recapitulate the biochemical and molecular hallmarks of the brain pathology. J Neurochem 2009; 109(1): 135-147
82. Jeyakumar M, Norflus F, Tifft CJ, et al. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 2001; 97(1): 327-329
83. Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009; 6(2): e1000029.
84. Bapat SA, Mishra GC. Stem cell pharmacogenomics: a reality check on stem cell therapy. Curr Opin Mol Ther 2005; 7(6): 551-556
85. Breyner NM, Hell RC, Carvalho LR, et al. Effect of a three-dimensional chitosan porous scaffold on the differentiation of mesenchymal stem cells into chondrocytes. Cells Tissues Organs 2009; [In press].
86. Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy 2009; [In press].
87. Snyderman R, Williams RS. Prospective medicine: the next health care transformation. Acad Med 2003; 78(11): 1079-1084
88. Matushansky I, Hernando E, Socci ND, et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 2007; 117(11): 3248-3257
89. Ianosi G, Neagoe D, Buteicǎ E, et al. Giant retroperitoneal sarcomas. Rom J Morphol Embryol 2007; 48(3): 303-308
90. Behroozan DS, Glaich A, Goldberg LH. Dermatofibrosarcoma protuberans following tanning bed use. J Drugs Dermatol 2005; 4(6): 751-754
91. Dittmer A, Hohlfeld K, Lützkendorf J, et al. Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10. Cell Mol Life Sci 2009; 66(18): 3053-3065
92. Mishra PJ, Mishra PJ, Humeniuk R, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 2008; 68(11): 4331-4339
93. Condic ML, Rao M. Regulatory issues for personalized pluripotent cells. Stem Cells 2008; 26(11): 2753-2758
94. Nakajima F, Tokunaga K, Nakatsuji N. Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells 2007; 25(4): 983-985
95. Drukker M, Benvenisty N. The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol 2004; 22(3): 136-141
96. Klimanskaya I, Rosenthal N, Lanza R. Derive and conquer: sourcing and differentiating stem cells for therapeutic applications. Nat Rev Drug Discov 2008; 7(2): 131-142
97. Zhang DY, Ye F, Gao L, et al. Proteomics, pathway array and signaling network-based medicine in cancer. Cell Div 2009; 4: 20.
98. Kreiner T, Buck KT. Moving toward whole-genome analysis: a technology perspective. Am J Health Syst Pharm 2005; 62(3): 296-305.
99. Arbab AS, Janic B, Haller J, et al. In vivo cellular imaging for translational medical research. Curr Med Imaging Rev 2009; 5(1): 19-38.
100. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105(5): 2214-2219
101. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105(10): 4120-4126
102. Spaggiari GM, Abdelrazik H, Becchetti F, et al. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009; 113(26): 6576-6583
103. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107(1): 367-372
104. Rasmusson I, Ringdén O, Sundberg B, et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76(8): 1208-1213
105. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, et al. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008; 26(1): 99-107.
106. Zeiter S, Lezuo P, Ito K. Effect of TGF beta1, BMP-2 and hydraulic pressure on chondrogenic differentiation of bovine bone marrow mesenchymal stromal cells. Biorheology 2009; 46(1): 45-55.